AORT Artivion, Inc. logo

AORT Artivion, Inc.

Healthcare
$22.46-1.36%ClosedMarket Cap: $1.09B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

184.47

PEG

1.07

P/B

2.40

P/S

2.38

EV/EBITDA

20.87

DCF Value

$-1.97

FCF Yield

1.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

62.9%

Operating Margin

7.8%

Net Margin

2.5%

ROE

2.7%

ROA

1.3%

ROIC

3.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$116.3M$1.4M$
Q4 null$116.0M$2.4M$
FY null$441.3M$9.8M$
Q3 null$113.4M$6.5M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$53.00

Target (Median)

$53.00

Target Range

$51.00 - $55.00

2 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
CitizensMarket Outperform
2026-05-08
NeedhamBuy
2026-05-08
Ladenburg ThalmannBuy
2026-04-10
NeedhamBuy
2026-04-07
Canaccord GenuityBuy
2026-02-13

Trading Activity

Insider Trades

View All
SEMEDO ANTHONY B.director
SellWed May 20
Salveson Jon Wdirector
SellWed May 20
Hoff Elizabeth Adirector
SellWed May 20
Burbank Jeffrey Hdirector
SellWed May 20
Bullock Jamesdirector
SellWed May 20

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.40

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Peers